Ming Guo1, Abha Khanna1, Agata A Tinnirello1, Jessica Hwang2, Ping Zhang3, Li Xu3, Guojun Li3, Kristina R Dahlstrom4, Erich M Sturgis5, John Stewart1. 1. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Medicine-Epidemiology and Population Sciences, Baylor College of Medicine, Houston, Texas. 5. Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas.
Abstract
BACKGROUND: This study evaluated the detection accuracy of the Cobas human papillomavirus (HPV) assay for high-risk human papillomavirus (hrHPV) and HPV-16 in head and neck fine-needle aspiration (FNA) specimens with squamous cell carcinoma. METHODS: Head and neck FNA biopsy specimens from 2012 to 2020 were retrospectively collected. Cobas HPV testing was performed on 90 FNA specimens with valid Cervista HPV testing results. Results of Cobas HPV and Cervista HPV assays were compared. A Linear Array or SPF10-LiPA25 HPV genotyping assay resolved cases with discrepant results. The κ value and accuracy of Cobas HPV testing were calculated. The accuracy of the Cobas HPV assay was also determined in 42 FNA needle-rinse specimens. RESULTS: Cobas HPV was positive in 82% of the FNA specimens (74 of 90). The concordance between Cobas HPV and Cervista HPV test results was 88.9% (80 of 90) with substantial agreement (κ = 0.669; 95% CI, 0.481-0.856). With HPV genotyping confirmation in cases with discrepant results between the 2 HPV assays, Cobas HPV showed 100% sensitivity and specificity for hrHPV. HPV-16 was detected in 88% of HPV-positive cases (65 of 74). HPV genotyping confirmed 1 false-negative HPV-16 result and 1 false-positive HPV-16 result. Overall, the accuracy of Cobas HPV for HPV-16 was 97.8%. The accuracy of Cobas HPV in FNA needle-rinse specimens was 100%. CONCLUSIONS: The Cobas HPV assay is highly accurate for determining the HPV status in head and neck FNA specimens. FNA needle rinse is valid for Cobas HPV testing in patients with squamous cell carcinoma.
BACKGROUND: This study evaluated the detection accuracy of the Cobas human papillomavirus (HPV) assay for high-risk human papillomavirus (hrHPV) and HPV-16 in head and neck fine-needle aspiration (FNA) specimens with squamous cell carcinoma. METHODS: Head and neck FNA biopsy specimens from 2012 to 2020 were retrospectively collected. Cobas HPV testing was performed on 90 FNA specimens with valid Cervista HPV testing results. Results of Cobas HPV and Cervista HPV assays were compared. A Linear Array or SPF10-LiPA25 HPV genotyping assay resolved cases with discrepant results. The κ value and accuracy of Cobas HPV testing were calculated. The accuracy of the Cobas HPV assay was also determined in 42 FNA needle-rinse specimens. RESULTS: Cobas HPV was positive in 82% of the FNA specimens (74 of 90). The concordance between Cobas HPV and Cervista HPV test results was 88.9% (80 of 90) with substantial agreement (κ = 0.669; 95% CI, 0.481-0.856). With HPV genotyping confirmation in cases with discrepant results between the 2 HPV assays, Cobas HPV showed 100% sensitivity and specificity for hrHPV. HPV-16 was detected in 88% of HPV-positive cases (65 of 74). HPV genotyping confirmed 1 false-negative HPV-16 result and 1 false-positive HPV-16 result. Overall, the accuracy of Cobas HPV for HPV-16 was 97.8%. The accuracy of Cobas HPV in FNA needle-rinse specimens was 100%. CONCLUSIONS: The Cobas HPV assay is highly accurate for determining the HPV status in head and neck FNA specimens. FNA needle rinse is valid for Cobas HPV testing in patients with squamous cell carcinoma.
Authors: Rebecca Baldassarri; Ryan Aronberg; Angelique W Levi; Wendell G Yarbrough; Diane Kowalski; David Chhieng Journal: Am J Clin Pathol Date: 2015-05 Impact factor: 2.493
Authors: Mark H Einstein; Mark G Martens; Francisco A R Garcia; Daron G Ferris; Amy L Mitchell; Stephen P Day; Marilyn C Olson Journal: Gynecol Oncol Date: 2010-05-21 Impact factor: 5.482
Authors: Ming Guo; Abha Khanna; Jasreman Dhillon; Shobha J Patel; Jie Feng; Michelle D Williams; Diana M Bell; Yun Gong; Ruth L Katz; Erich M Sturgis; Gregg A Staerkel Journal: Cancer Cytopathol Date: 2013-12-11 Impact factor: 5.284
Authors: James S Lewis; Beth Beadle; Justin A Bishop; Rebecca D Chernock; Carol Colasacco; Christina Lacchetti; Joel Todd Moncur; James W Rocco; Mary R Schwartz; Raja R Seethala; Nicole E Thomas; William H Westra; William C Faquin Journal: Arch Pathol Lab Med Date: 2017-12-18 Impact factor: 5.534
Authors: Darcy A Kerr; Martha B Pitman; Brenda Sweeney; Ronald N Arpin; David C Wilbur; William C Faquin Journal: Cancer Cytopathol Date: 2013-11-20 Impact factor: 5.284
Authors: Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison Journal: N Engl J Med Date: 2007-05-10 Impact factor: 91.245
Authors: Nicolette Taku; Li Wang; Adam S Garden; David I Rosenthal; G Brandon Gunn; William H Morrison; C David Fuller; Jack Phan; Jay P Reddy; Amy C Moreno; Michael T Spiotto; Gregory Chronowski; Shalin J Shah; Lauren L Mayo; Neil D Gross; Renata Ferrarotto; X Ronald Zhu; Xiaodong Zhang; Steven J Frank Journal: Curr Treat Options Oncol Date: 2021-06-04